This is a combined synopsis/solicitation for commercial items for mRNA sequencing and methyl-bisulfite sequencing from submitted leaf tissue samples. The acquisition is a total small business set aside. Quotations are requested by August 5, 2026, 17:00 CD. The period of performance is from August 17, 2026, to August 16, 2027. Award will be made to the offeror representing the best value to the government based on lowest price technically acceptable criteria, considering price, technical acceptability, and past performance. Questions are due by July 27, 2026, 5:00 PM CDT.
The period of performance is from 08/17/2026 to 08/16/2027. Deliverables include QC reports, library prep, sequencer run statistics, and sequencing data, with specific due dates relative to sample receipt and QC confirmation.
Payment will be made by the government. Invoices should be submitted to the address shown in block 18a unless otherwise specified.
Award will be made to the offeror representing the best value to the government, evaluated based on the lowest price technically acceptable criteria.
Offerors must provide a detailed explanation of their ability to perform the required services and address any requirements they cannot accomplish. Past performance will be evaluated.
Failure to comply with certain clauses, including anti-discrimination and DEI compliance, may be grounds for contract termination for default.
Sample tissue will be submitted to the contractor on an as-needed basis via delivery service throughout the performance period.
Agency protests must be filed within the timeframes specified in FAR **** should first be submitted to the contracting officer within 10 business days.
Submitting a knowing false statement regarding compliance or eligibility may subject the offeror to liability under the False Claims Act and criminal liability.
